Sandoz
has announced the US Food and Drug Administration (FDA) approval and US launch
of levofloxacin tablets and levofloxacin in 5% dextrose injection.
Levofloxacin is an antibiotic indicated for use in adults 18 years or older to treat acute bacterial sinusitis community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, certain types of uncomplicated or complicated skin and skin-structure infections, chronic bacterial prostitis, inhalation anthrax, and certain types of urinary tract infections.
According to IMS Health, US sales for Levaquin Tablets and Levaquin Injection Pre-Mixed Solution were approximately USD 1.5 billion and USD 149 million, respectively, for the 12 months ending in April 2011. Sandoz will market levofloxacin tablets in 250 mg, 500 mg, and 750 mg strengths. Sandoz is marketing levofloxacin in 5% dextrose injection as a single-use, premixed solution in flexible containers.
Each bag contains a diluted solution with the equivalent of 250 mg, 500 mg, or 750 mg of levofloxacin in 5% dextrose.
Levofloxacin is an antibiotic indicated for use in adults 18 years or older to treat acute bacterial sinusitis community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, certain types of uncomplicated or complicated skin and skin-structure infections, chronic bacterial prostitis, inhalation anthrax, and certain types of urinary tract infections.
According to IMS Health, US sales for Levaquin Tablets and Levaquin Injection Pre-Mixed Solution were approximately USD 1.5 billion and USD 149 million, respectively, for the 12 months ending in April 2011. Sandoz will market levofloxacin tablets in 250 mg, 500 mg, and 750 mg strengths. Sandoz is marketing levofloxacin in 5% dextrose injection as a single-use, premixed solution in flexible containers.
Each bag contains a diluted solution with the equivalent of 250 mg, 500 mg, or 750 mg of levofloxacin in 5% dextrose.
No comments:
Post a Comment